Patients with vitiligo and alopecia areata face some of the widest coverage gaps in dermatology. Although both conditions have FDA-approved treatments, many plans continue to classify them as cosmetic and deny coverage entirely.
This DCAN paper documents the scope of the problem, reviews the clinical evidence that these are medical conditions with real physical and psychological consequences, and lays out policy recommendations for closing the gap.
This is sample copy — upload the paper PDF in the Media library and attach it to this resource from the site admin.
